US FDA Approves Pfizer's Tukysa for Breast Cancer Maintenance Therapy
PFE Pfizer Inc
$28.00 +1.82%
View chart & analysis → - 1The US Food and Drug Administration (FDA) has approved Pfizer's Tukysa for use in combination with other drugs as maintenance therapy for breast cancer.
- 2Clinical results showed Tukysa reduced the risk of disease progression or death by 35.9% compared to the control group.
- 3The Tukysa group achieved a median investigator-assessed progression-free survival of 24.9 months.
So what's the key point?
Pfizer's breast cancer treatment has received approval in the US for use alongside other medications. Using this drug is associated with a 35.9% reduction in the risk of disease progression or death.
Source Nasdaq +1 · View original ↗
Today's 5 AI picks, all freeNothing hidden: past picks and how they did against the S&P 500.